sec filing
TR
NASDAQ · TRDA
Entrada Therapeutics, Inc.
Healthcare · Biotechnology
$7.57
Down-$0.03 (-0.39%)
Updated Aug 23, 2026, 4:30 AM
SID Score
5.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 413.53M
- P/E ratio
- -4.34
- Dividend yield
- 0.00%
- 52-week range
- $5.02 – $16.45
- Volume
- 141.02K
- Avg. volume
- 275.51K
Price performance
TRDA price history
1M range · 20 trading sessions · Daily adjusted prices
TRDA closed at $7.57 after 20 trading sessions, up 24.51% for the selected period.
- Last close
- $7.57
- Period change
- +24.51%
- Period low
- $5.83
- Period high
- $7.78
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $7.64 | $7.735 | $7.44 | $7.57 | 141.02K |
| Aug 20, 2026 | $7.76 | $7.765 | $7.30 | $7.60 | 250.04K |
| Aug 19, 2026 | $7.49 | $7.79 | $7.395 | $7.78 | 241.84K |
| Aug 18, 2026 | $7.21 | $7.43 | $7.16 | $7.27 | 129.76K |
| Aug 17, 2026 | $7.33 | $7.56 | $7.25 | $7.32 | 193.11K |
| Aug 14, 2026 | $7.45 | $7.53 | $7.21 | $7.46 | 237.99K |
| Aug 13, 2026 | $7.74 | $7.765 | $7.369 | $7.45 | 236.44K |
| Aug 12, 2026 | $7.03 | $7.68 | $6.93 | $7.67 | 263.66K |
| Aug 11, 2026 | $7.00 | $7.27 | $6.93 | $7.04 | 264.1K |
| Aug 10, 2026 | $6.87 | $7.26 | $6.83 | $6.95 | 411.84K |
| Aug 7, 2026 | $6.94 | $7.085 | $6.75 | $6.87 | 458.07K |
| Aug 6, 2026 | $7.05 | $7.11 | $6.74 | $6.87 | 269.97K |
| Aug 5, 2026 | $7.47 | $7.47 | $6.85 | $7.06 | 591.55K |
| Aug 4, 2026 | $6.945 | $7.97 | $6.945 | $7.24 | 663.13K |
| Aug 3, 2026 | $6.83 | $7.31 | $6.64 | $7.26 | 500.5K |
| Jul 31, 2026 | $6.71 | $6.90 | $6.49 | $6.79 | 352.6K |
| Jul 30, 2026 | $6.55 | $7.04 | $6.45 | $6.77 | 594.75K |
| Jul 29, 2026 | $5.78 | $6.73 | $5.78 | $6.55 | 435.42K |
| Jul 28, 2026 | $6.10 | $6.11 | $5.72 | $5.83 | 445.75K |
| Jul 27, 2026 | $5.95 | $6.23 | $5.95 | $6.08 | 446.76K |
Latest TRDA news
The latest Smart Investors Daily articles mentioning TRDA.
Stock researchResearch & News · SEC Filings
Loading stock research…